

## **TATE & LYLE PLC – Trading Update prior to Closed Period**

**29 March 2007**

Before entering its closed period for the year ending 31 March 2007 and prior to briefing stockbrokers' analysts, Tate & Lyle issues the following routine trading update. The preliminary announcement of results for the year ending 31 March 2007 will be made on 23 May 2007.

### **TRADING**

Since the update on 23 January 2007 the Group's overall trading performance has been in line with market expectations and has continued to comfortably exceed the corresponding period of the prior year.

As previously indicated, sales and profits of SPLENDA® Sucralose for the year to 31 March 2007 are expected to only modestly exceed the prior year. We are continuing to work with our customers on product innovation and will provide an update on our SPLENDA® Sucralose business at our results presentation on 23 May 2007.

### **OTHER ITEMS**

The renunciation of beet sugar quota by Eastern Sugar (announced on 10 October 2006) has been formally agreed with the EU restructuring fund and Eastern Sugar will be treated as a discontinued business in the financial results for the year ending 31 March 2007. Tate & Lyle's share of net cash proceeds from the restructuring fund of approximately £51 million will be payable in two instalments in the financial year to 31 March 2009. The net exceptional gain on closure is estimated at £15 million and will be reported in the year to 31 March 2007.

Following the decision to cease production of citric acid at the site in Selby, Yorkshire, a fundamental review has been undertaken of the astaxanthin business carried on at the same site. Following this review it has been decided to take an impairment charge on our investment in the astaxanthin business. This charge together with the closure costs for the citric plant are expected to result in an exceptional charge of approximately £35 million in the year to 31 March 2007.

The disposal of Tate & Lyle Canada Ltd (announced on 14 February 2007) ("Redpath") remains subject to regulatory approvals. Our expectation remains that completion will take place early in the next financial year and will result in an exceptional gain of approximately £50 million in the year ending 31 March 2008. Redpath will be treated as a discontinued business in the financial results for the year ending 31 March 2007.

We continue to make progress in exploring the possible full or partial disposal of Food & Industrial Ingredients, Europe (announced on 25 October 2006). A further update is planned within the next few weeks.

A conference call for analysts and investors will be held at 8.30am today. The call will be hosted by John Nicholas, Group Finance Director and Mark Robinson, Director of Investor Relations. Participants are requested to dial in at least 5 minutes before the commencement of the call. Dial in details are:

Participant dial in number: +44(0) 20 7138 0817  
Replay telephone number: +44(0) 20 7806 1970  
Replay passcode: 1400984#

The replay of this call will be available for 7 days until 4 April 2007.

**END**

**CONTACTS**

Mark Robinson, Director of Investor Relations  
Tel: 020 7626 6525 or Mobile: 07793 515861

Ferne Hudson, Head of Media and Public Relations  
Tel: 020 7626 6525 or Mobile: 07713 067433

About Tate & Lyle: Tate & Lyle is a world leading manufacturer of renewable food and industrial ingredients. It uses innovative technology to transform corn, wheat and sugar into value-added ingredients for customers in the food, beverage, pharmaceutical, cosmetic, paper, packaging and building industries. The Company is a leader in cereal sweeteners and starches, sugar refining, value added food and industrial ingredients, and citric acid. Tate & Lyle is the world number-one in industrial starches and is the sole manufacturer of SPLENDA® Sucralose.

Headquartered in London, Tate & Lyle is listed on the London Stock Exchange under the symbol TATE.L. In the US its ADRs trade under TATYY. The Company operates more than 65 production facilities in 29 countries, throughout Europe, the Americas and South East Asia. It employs 7,000 people in its subsidiaries with a further 4,800 employed in joint ventures. Sales in the year to 31 March 2006 totalled £3.7 billion. Additional information can be found on this website [www.tateandlyle.com](http://www.tateandlyle.com).

SPLENDA® and the SPLENDA® logo are trademarks of McNeil Nutritionals, LLC